STOCK TITAN

60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis

SXTP NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
89 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
+152% close of January 22, 2026
1-year change
-88.4% closing prices, November 20, 2025 to November 20, 2026
1-month change
-49.2% closing prices, October 20, 2026 to November 20, 2026

Company Description

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) is a specialty pharmaceutical company that focuses on developing and commercializing new medicines for the treatment and prevention of vector-borne diseases. According to company disclosures, 60 Degrees Pharmaceuticals, Inc. (also referred to as 60 Degrees Pharma) concentrates on conditions transmitted by vectors such as ticks and mosquitoes, aligning with its presence in the medicinal and botanical manufacturing segment of the broader manufacturing sector.

Founded in 2010, 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C., with a subsidiary in Australia. The company reports that it collaborates with prominent research and academic organizations in the United States and Australia, and in some disclosures also notes collaborations with organizations in Singapore. Its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols SXTP and SXTPW, respectively, as reflected in its SEC filings.

Core focus on vector-borne disease

Across multiple public statements, 60 Degrees Pharmaceuticals, Inc. describes itself as a pharmaceutical company focused on developing new medicines for vector-borne disease. These include diseases caused by parasites and pathogens transmitted by arthropod vectors such as ticks and mosquitoes. The company’s activities include both the commercialization of an approved product and the sponsorship of clinical trials intended to evaluate potential new uses of its lead molecule.

The firm’s lead product is ARAKODA® (tafenoquine), an antimalarial drug. The company states that it achieved U.S. Food and Drug Administration (FDA) approval of ARAKODA (tafenoquine) for malaria prevention in 2018. ARAKODA is described as commercially available in the United States and Australia, where tafenoquine is also approved for malaria prophylaxis under the product name KODATEF® in Australia. Both products are reported to be distributed through pharmaceutical wholesaler networks and dispensed as prescription-only medicines at retail pharmacies.

Lead product: ARAKODA® (tafenoquine) for malaria prophylaxis

Company materials describe ARAKODA (tafenoquine) as an antimalarial indicated for the prophylaxis of malaria in patients 18 years of age and older. Tafenoquine was discovered by the Walter Reed Army Institute of Research, and the company notes that the safety of the approved regimen for malaria prophylaxis has been assessed in multiple randomized, double-blind, active comparator or placebo-controlled trials of up to six months’ duration.

Public information from the company explains that tafenoquine has a long terminal half-life of approximately 16 days, and that this characteristic may offer potential advantages for less-frequent dosing in malaria prophylaxis, as described by the U.S. Centers for Disease Control and Prevention in the materials cited by the company. The firm also outlines a specific dosing regimen for individuals at risk of contracting malaria, involving a loading phase followed by weekly dosing during exposure and a final dose after travel.

Company disclosures emphasize that ARAKODA is not suitable for all patients. They highlight contraindications, including in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or unknown G6PD status, certain psychiatric histories, and known hypersensitivity to tafenoquine or related compounds. The company also details warnings and precautions related to hemolytic anemia, methemoglobinemia, psychiatric effects, hypersensitivity reactions, and delayed adverse reactions due to the long half-life of tafenoquine. Frequently reported adverse reactions include headache, dizziness, back pain, gastrointestinal symptoms, and certain laboratory abnormalities.

Expansion into babesiosis and other vector-borne indications

In addition to malaria prophylaxis, 60 Degrees Pharmaceuticals, Inc. sponsors clinical research programs involving tafenoquine in patients with babesiosis, a tick-borne illness caused by Babesia parasites. Company announcements describe several clinical trials, including:

  • An open-label, expanded access study (NCT06478641) of tafenoquine in combination with conventional treatments in high-risk patients with relapsing babesiosis.
  • A double-blind, randomized, multi-site placebo-controlled trial (NCT06207370) in hospitalized patients diagnosed with babesiosis.
  • The B-FREE Chronic Babesiosis Study (NCT06656351), a Phase 2 open-label trial evaluating the efficacy and safety of the ARAKODA regimen of tafenoquine over 90 days in patients diagnosed with chronic babesiosis, with endpoints focused on fatigue and parasite eradication.

Company communications repeatedly state that tafenoquine has not been proven to be effective for the treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for any babesiosis indication. The babesiosis studies are described as intended to evaluate safety and efficacy and to help clarify the clinical significance of Babesia infection in various patient populations.

60 Degrees Pharmaceuticals, Inc. has also reported sponsoring or funding research related to Babesia infection and chronic fatigue, including a study at North Carolina State University that examined Babesia infection in patients with chronic fatigue. The company notes that this work contributes to ongoing efforts within the vector-borne disease community to understand potential links between Babesia infection and chronic disease.

Collaborations and research relationships

Public statements from the company describe collaborations with research and academic organizations in the United States and Australia, and in some cases also in Singapore. Examples mentioned include a sponsored research agreement with Tulane University to evaluate tafenoquine activity against Borrelia (associated with Lyme disease) and Bartonella bacteria, and clinical trial agreements with the Icahn School of Medicine at Mount Sinai in New York City for babesiosis studies.

The company also notes that its mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors, including Knight Therapeutics Inc., which it identifies as a Canadian-based Pan-American specialty pharmaceutical company. These disclosures highlight the role of external partners in supporting research and development activities around vector-borne diseases.

Corporate and listing information

According to an 8-K filing, 60 Degrees Pharmaceuticals, Inc. is incorporated in Delaware and is an emerging growth company under U.S. securities regulations. Its common stock, with a par value of $0.0001 per share, and its warrants are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Stock Market LLC under the symbols SXTP and SXTPW.

The company has disclosed corporate actions such as a reverse stock split of its common stock, approved by stockholders and its board of directors, with the stated purpose of helping the company comply with Nasdaq’s minimum bid price requirement for continued listing. The reverse split affects issued and outstanding shares and related equity-linked securities but, as described, does not change the total number of authorized shares or the par value of the common stock.

Business activities and pipeline orientation

Across its news releases, 60 Degrees Pharmaceuticals, Inc. describes its business as specializing in developing and commercializing new medicines for vector-borne disease. The company’s activities include:

  • Marketing and commercial support for ARAKODA (tafenoquine) for malaria prophylaxis in the United States, with references to sales and marketing initiatives and pharmacy deliveries.
  • Clinical development programs evaluating tafenoquine in babesiosis, including chronic and relapsing forms of the disease.
  • Sponsored research and collaborations focused on vector-borne pathogens and related chronic conditions.

In addition, the company has described initiatives such as expanding its inside sales team for ARAKODA, engaging in partnerships to broaden offer visibility for patients and prescribers, and implementing digital marketing campaigns aimed at prescriber audiences. These activities are presented as part of the company’s efforts to support the commercial performance of its approved product and to advance its research programs.

Regulatory and safety considerations

Because its lead product is a prescription antimalarial, 60 Degrees Pharmaceuticals, Inc. provides extensive safety information in its public communications. This includes contraindications, warnings, and precautions associated with tafenoquine, as well as guidance related to specific populations such as pregnant women and lactating mothers of G6PD-deficient infants. The company also notes potential drug interactions, advising avoidance of co-administration with drugs that are substrates of certain transporters.

In its descriptions of babesiosis research, the company reiterates that no FDA-approved treatment or vaccine exists specifically for babesiosis and that chronic babesiosis and related conditions are areas of unmet medical need. Its clinical trials are framed as efforts to generate data on the safety and efficacy of tafenoquine in these settings and to clarify the size and characteristics of the patient populations affected.

Position within the medicinal and botanical manufacturing industry

Within the medicinal and botanical manufacturing industry, 60 Degrees Pharmaceuticals, Inc. presents itself as a company with a focused therapeutic area: vector-borne disease. Rather than describing a broad therapeutic portfolio, its public information centers on tafenoquine-based products and associated research programs. This focus, combined with collaborations with academic and governmental partners, shapes its profile as a specialty pharmaceutical company operating at the intersection of infectious disease, tropical medicine, and vector-borne illness.

Stock Performance

$0.4682
-6.36%
-0.0318
Last updated: at
-88.4%
Performance 1 year
4.5M
Shares outstanding As of November 16, 2026.

60 Degrees Pharmaceuticals (SXTP) closed at $0.4682 on November 20, 2026. Over the past 12 months, the price has lost 88.4%.

See what a $1,000 investment in SXTP would be worth today

Average down calculator for SXTP

SXTP Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

60 Degrees Pharmaceuticals has 10 recent news articles. Of the recent coverage, 2 articles coincided with positive price movement and 8 with negative movement. Key topics include partnership, earnings, private placement. View all SXTP news →

SEC Filings

60 Degrees Pharmaceuticals has filed 10 recent SEC filings, including 6 Form 8-K, 3 Form SCHEDULE 13G/A, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all SXTP SEC filings →

Financial Highlights

60 Degrees Pharmaceuticals generated $1.0M in revenue in FY2025, retaining a 22.3% gross margin, operating income reached -$7.8M, and net income was -$7.4M. Diluted earnings per share stood at -$11.73. The company generated -$6.8M in operating cash flow. The current ratio was 2.65, measuring current assets divided by current liabilities.

$1.0M
Revenue (FY2025)
-$7.4M
Net Income (FY2025)
-$6.8M
Operating Cash Flow

Upcoming Events

JAN
2027
January 2027 Regulatory

FDA meeting request

Company plans to request an FDA meeting in January 2027 to discuss a supplemental approval filing and accelerated pathway.
JAN
2027
January 2027 Clinical

Severe babesiosis results

Company plans to report severe babesiosis trial endpoint results in January 2027 from the 30-patient enrollment study.
JAN
2027
January 2027 Clinical

Hospital study unblinding

Unblinding of 60 Degrees' randomized hospital babesiosis study in Jan 2027; results will inform plans to seek an FDA meeting.

60 Degrees Pharmaceuticals has 3 upcoming scheduled events. The next event, "FDA meeting request", is expected in January 2027. Investors can track these dates to stay informed about potential catalysts that may affect the SXTP stock price.

Short Interest History

Last 12 Months

Short interest in 60 Degrees Pharmaceuticals (SXTP) currently stands at 255.1 thousand shares, up 88.4% from the previous reporting period, representing 9.0% of the float. Since the latest stock split, short interest has increased by 137.8%, measured from February 2026.

Days to Cover History

Last 12 Months

Days to cover for 60 Degrees Pharmaceuticals (SXTP) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 28.1%. Across the settlements charted above, it has ranged from 1.0 to 5.7 days.

SXTP Company Profile & Sector Positioning

60 Degrees Pharmaceuticals (SXTP) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing SXTP often look at related companies in the same sector, including Calidi Biotherapeutics, Inc. (CLDI), Jupiter Neurosciences, Inc. (JUNS), Propanc Biopharma, Inc. (PPCB), Kairos Pharma, Ltd. (KAPA), and XORTX Therapeutics Inc. (XRTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate SXTP's relative position within its industry.

Frequently Asked Questions

The current stock price of 60 Degrees Pharmaceuticals (SXTP) is $0.4682 as of November 20, 2026.

The market cap of 60 Degrees Pharmaceuticals (SXTP) is approximately $1.6M. Learn more about what market capitalization means .

The FY2025 revenue of 60 Degrees Pharmaceuticals (SXTP) is $1.0M, from its most recent completed fiscal year.

The FY2025 net income of 60 Degrees Pharmaceuticals (SXTP) is -$7.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of 60 Degrees Pharmaceuticals (SXTP) is -$11.73 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of 60 Degrees Pharmaceuticals (SXTP) is -$6.8M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The gross profit margin of 60 Degrees Pharmaceuticals (SXTP) is 22.3% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of 60 Degrees Pharmaceuticals (SXTP), current assets divided by current liabilities, was 2.65 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of 60 Degrees Pharmaceuticals (SXTP) is $224K for FY2025, its most recent completed fiscal year.

The operating income of 60 Degrees Pharmaceuticals (SXTP) is -$7.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

60 Degrees Pharmaceuticals, Inc. describes itself as a specialty pharmaceutical company focused on developing and commercializing new medicines for the treatment and prevention of vector-borne disease. Its public materials emphasize work on conditions transmitted by vectors such as ticks and mosquitoes, combining commercialization of an approved antimalarial drug with clinical research programs in related infectious diseases.

The company identifies ARAKODAae (tafenoquine) as its lead product. ARAKODA is an antimalarial indicated for the prophylaxis of malaria in adults and, according to the company, received U.S. Food and Drug Administration approval for malaria prevention in 2018. Tafenoquine for malaria prophylaxis is also approved in Australia under the product name KODATEFae.

Company disclosures describe ARAKODA (tafenoquine) as an antimalarial drug indicated for malaria prophylaxis in patients 18 years of age and older. The safety of the approved regimen has been evaluated in several randomized, double-blind, active comparator or placebo-controlled trials of up to six months duration. The company notes that tafenoquine has a long terminal half-life of approximately 16 days, which may allow less-frequent dosing for prophylaxis, and that it is available as a prescription-only medicine in the United States and Australia.

No. In its public statements, 60 Degrees Pharmaceuticals, Inc. repeatedly notes that tafenoquine has not been proven to be effective for the treatment or prevention of babesiosis and is not approved by the U.S. Food and Drug Administration for any babesiosis indication. The company sponsors clinical trials to evaluate tafenoquine in patients with babesiosis, but these studies are exploratory and do not change the approved indication.

Public disclosures state that 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington, D.C. The company also notes that it has a subsidiary in Australia and, in some communications, that it collaborates with organizations in Singapore.

According to its SEC filings, 60 Degrees Pharmaceuticals, Inc. has its common stock and warrants registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on The Nasdaq Stock Market LLC. The common stock trades under the symbol SXTP and the warrants trade under the symbol SXTPW.

The company states in multiple public communications that it was founded in 2010. This founding year is presented as part of its corporate background in descriptions of its history and mission in vector-borne disease therapeutics.

Company materials emphasize that ARAKODA should not be used in patients with G6PD deficiency or unknown G6PD status, in certain psychiatric histories, or in those with known hypersensitivity to tafenoquine, other 8-aminoquinolines, or any component of the product. They also describe risks of hemolytic anemia, methemoglobinemia, psychiatric effects, hypersensitivity reactions, and delayed adverse reactions due to the long half-life of tafenoquine, and they list common adverse reactions such as headache, dizziness, gastrointestinal symptoms, and sleep or mood changes.

The company reports collaborations with research and academic organizations in the United States and Australia, and in some cases also in Singapore. Examples include a clinical trial agreement with the Icahn School of Medicine at Mount Sinai for babesiosis studies and a sponsored research agreement with Tulane University to evaluate tafenoquine activity against Borrelia and Bartonella. The company also notes that its mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors such as Knight Therapeutics Inc.